
Journal of Medicinal Chemistry p. 3321 - 3332 (1993)
Update date:2022-09-26
Topics:
Daines, Robert A.
Chambers, Pamela A.
Pendrak, Israil
Jakas, Dalia R.
Sarau, Henry M.
et al.
A series of trisubstituted pyridines have been prepared that exhibit in vitro leukotriene B4 (LTB4, 1) receptor antagonist activity.Previous disubstituted pyridines from these labs showed high affinity for the LTB4 receptor but demonstrated agonist activity in functional assays (e.g., 2, Ki = 1 nM).Compound 4, the initial lead compound of this new series, showed only modest affinity by comparison (Ki = 282 nM); however, 4 was a receptor antagonist with no demonstrable agonist activity up to 10 μM.Subsequent modifications of the lipid tail and aryl head group region led to the discovery of aniline 50 (SB 201146).This compound, also free of agonist activity, possesses high affinity for the LTB4 receptor (Ki = 4.7 nM).
View MoreTaizhou Shengxing Chempharm Co.,Ltd
Contact:+86-576-88516600
Address:Yantou Chemical Zone Jiaojiang Taizhou Zhejiang China
suzhou chukai pharmateach co,.ltd
Contact:86-512-88812511
Address:Building 3, Wujiang Scientific Innovation Park, 2358 Changan Rd, Wujiang 215200, Jiangsu Province, P. R. China
Shenzhen HwaGen Pharmaceutical Co., Ltd
website:http://www.rafflespt.com
Contact:+86-752-5538396
Address:Guangdong Huizhou China
Hangzhou Share Chemical Co., Ltd(expird)
Contact:+86-57187093700
Address:Hang Xing Road
ShanDong XinDa Chemical CO.,LTD(expird)
Contact:086-0311-87580543
Address:No.168, High Technology Development Zone Jinan Shandong China
Doi:10.1021/jo00040a064
(1992)Doi:10.1021/ja3113752
(2013)Doi:10.1002/aoc.2952
(2013)Doi:10.1021/jo302549v
(2013)Doi:10.1246/cl.1992.807
(1992)Doi:10.1021/ja00975a029
(1966)